Objectives:
- To evaluate the clinical value of CGP in “real-world” practice for offering more therapeutic options to cancer patients and a broader access to precision oncology
- To evaluate the feasibility of implementing a fully standardised CGP wet-lab performance, data analysis, clinical interpretation, therapy recommendation and reporting among NGS labs
- To describe and quantify the uptake of innovative treatments and the inclusion in clinical trials recommended by a national or international MTB guided by the CGP
- To work in a multi-stakeholder approach to attract more innovative treatments and clinical trials to countries of the EU
Aim of this working package is to evaluate the clinical value of Comprehensive Genomic Profiling (CGP) in “real-world” practice for offering more therapeutic options to cancer patients and a broader access to precision oncology. We will evaluate the feasibility of implementing a fully standardized CGP wet-lab performance, data analysis, clinical interpretation, therapy recommendation and reporting among NGS labs. Another objective Is to describe and quantify the uptake of innovative treatments and the inclusion in clinical trials recommended by a national or international Molecular Tumour Board (MTB) guided by the CGP. Working in a multi-stakeholder approach will surely help achieve these goals and attract more innovative treatments and clinical trials to EU countries.
CGP of solid tumours will be performed using the Illumina platform that covers more than 500 cancer genes and all types of genomic alterations. Data for up to 1000 patients generated in real world will be collected and analysed and targeted treatment recommendations based on the CGP results will be done by the Belgian national MTB.
